Karin Wåhlander
AstraZeneca Research and Development Mölndal
Mölndal
Sweden
Name/email consistency: high
- Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. Wåhlander, K., Eriksson, H., Lundström, T., Billing Clason, S., Wall, U., Nyström, P., Wessman, P., Schulman, S. Br. J. Haematol. (2006)
- Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Wåhlander, K., Eriksson-Lepkowska, M., Nyström, P., Eriksson, U.G., Sarich, T.C., Badimon, J.J., Kalies, I., Elg, M., Bylock, A. Thromb. Haemost. (2006)
- No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Wåhlander, K., Eriksson-Lepkowska, M., Frison, L., Fager, G., Eriksson, U.G. Clin. Pharmacokinet (2003)
- Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Wåhlander, K., Larson, G., Lindahl, T.L., Andersson, C., Frison, L., Gustafsson, D., Bylock, A., Eriksson, B.I. Thromb. Haemost. (2002)
- Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Wåhlander, K., Lapidus, L., Olsson, C.G., Thuresson, A., Eriksson, U.G., Larson, G., Eriksson, H. Thromb. Res. (2002)
